Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + QL1706 + Bevacizumab in Locally Advanced or Oligometastatic HCC
NCT07882056Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2026
- Primary completion
- Aug 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate per RECIST 1.1. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07882056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882056.